Verona Pharma meeting its primary objective in its ‘add-on’ Phase IIa trial with RPL554 in COPD patients is extremely encouraging and follows the positive results from all of its clinical trials with a new proprietary suspension formulation of RPL554. The trial met both its primary and secondary objectives and continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment of respiratory disease. Ver ....
10 May 2016
Stellar results from ‘add-on’ Phase IIa trial with RPL554
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Stellar results from ‘add-on’ Phase IIa trial with RPL554
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
10 May 2016 -
Author:
Sheena Berry -
Pages:
3
Verona Pharma meeting its primary objective in its ‘add-on’ Phase IIa trial with RPL554 in COPD patients is extremely encouraging and follows the positive results from all of its clinical trials with a new proprietary suspension formulation of RPL554. The trial met both its primary and secondary objectives and continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment of respiratory disease. Ver ....